AstraZeneca ( (GB:AZN) ) just unveiled an update.
AstraZeneca’s Imfinzi has been approved by the FDA as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) in the US, following the successful NIAGARA Phase III trial. This approval marks a significant advancement in treatment, offering a new standard of care by reducing the risk of disease recurrence and death, and is expected to transform clinical approaches to MIBC, providing new hope for patients and stakeholders.
More about AstraZeneca
AstraZeneca is a leading global biopharmaceutical company specializing in the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in oncology, cardiovascular, renal, and metabolism, and respiratory areas. The company is a pioneer in immuno-oncology, with a comprehensive portfolio aimed at overcoming the evasion of the anti-tumor immune response and stimulating the body’s immune system to attack tumors.
YTD Price Performance: 10.64%
Average Trading Volume: 2,777,481
Technical Sentiment Signal: Strong Sell
Current Market Cap: £177B
See more data about AZN stock on TipRanks’ Stock Analysis page.